[go: up one dir, main page]

WO2001074341A3 - Composition for treating allergic and inflammatory conditions with cough containing a non-sedating histamine and an expectorant - Google Patents

Composition for treating allergic and inflammatory conditions with cough containing a non-sedating histamine and an expectorant Download PDF

Info

Publication number
WO2001074341A3
WO2001074341A3 PCT/US2001/010019 US0110019W WO0174341A3 WO 2001074341 A3 WO2001074341 A3 WO 2001074341A3 US 0110019 W US0110019 W US 0110019W WO 0174341 A3 WO0174341 A3 WO 0174341A3
Authority
WO
WIPO (PCT)
Prior art keywords
expectorant
inflammatory conditions
cough
composition
treating allergic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/010019
Other languages
French (fr)
Other versions
WO2001074341A2 (en
Inventor
Lugo Sergio Rolando Ulloa
Ramos Jose De Jesus Villacampa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Priority to NZ520826A priority Critical patent/NZ520826A/en
Priority to AU4786701A priority patent/AU4786701A/en
Priority to AU2001247867A priority patent/AU2001247867B2/en
Publication of WO2001074341A2 publication Critical patent/WO2001074341A2/en
Publication of WO2001074341A3 publication Critical patent/WO2001074341A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

The use of a non-sedating antihistamine in combination with an expectorant for the preparation of a medicament for treatment and/or prevention allergic and inflammatory conditions with cough in humans in need of such treating and/or preventing which comprise an effective amount of a non-sedating antihistamine, preferably loratadine, in combination with an expectorant, preferably ambroxol are disclosed. Pharmaceutical compositions for treating and/or preventing allergic and inflammatory conditions with cough in humans comprising an effective amount of a non-sedating antihistamine in combination with an expectorant and a pharmaceutically acceptable carrier are also disclosed.
PCT/US2001/010019 2000-03-30 2001-03-28 Composition for treating allergic and inflammatory conditions with cough containing a non-sedating histamine and an expectorant Ceased WO2001074341A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
NZ520826A NZ520826A (en) 2000-03-30 2001-03-28 Compositions and methods for treating allergic and inflammatory conditions with cough containing a non-sedating histamine and an expectorant
AU4786701A AU4786701A (en) 2000-03-30 2001-03-28 Compositions and methods for treating allergic and inflammatory conditions with cough
AU2001247867A AU2001247867B2 (en) 2000-03-30 2001-03-28 Composition for treating allergic and inflammatory conditions with cough containing a non-sedating histamine and an expectorant

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19331000P 2000-03-30 2000-03-30
US60/193,310 2000-03-30

Publications (2)

Publication Number Publication Date
WO2001074341A2 WO2001074341A2 (en) 2001-10-11
WO2001074341A3 true WO2001074341A3 (en) 2002-05-16

Family

ID=22713096

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/010019 Ceased WO2001074341A2 (en) 2000-03-30 2001-03-28 Composition for treating allergic and inflammatory conditions with cough containing a non-sedating histamine and an expectorant

Country Status (13)

Country Link
CN (1) CN1422162A (en)
AR (1) AR025308A1 (en)
AU (2) AU4786701A (en)
BR (1) BR0003648A (en)
CO (1) CO5200779A1 (en)
CR (1) CR6232A (en)
NZ (1) NZ520826A (en)
PA (1) PA8500101A1 (en)
PE (1) PE20010576A1 (en)
SG (1) SG96611A1 (en)
TW (1) TWI243671B (en)
WO (1) WO2001074341A2 (en)
ZA (1) ZA200102605B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1323662C (en) * 2004-06-18 2007-07-04 江苏恒瑞医药股份有限公司 Pharmaceutical composition containing ambroxol and erdosteine or acetylcysteine and application thereof
WO2005123052A1 (en) * 2004-06-18 2005-12-29 Jiangsu Hengrui Medicine Co., Ltd. Drug composition containing ambroxol and erdosteine or acetylcysteine

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985004589A1 (en) * 1984-04-09 1985-10-24 Abraham Sunshine Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
WO1988008302A1 (en) * 1987-04-24 1988-11-03 Abraham Sunshine Cough/cold mixtures comprising non-sedating antihistamine drugs
WO1988009656A1 (en) * 1987-06-08 1988-12-15 Abraham Sunshine Cough/cold mixtures comprising non-sedating antihistamine drugs
WO1995007103A1 (en) * 1993-09-07 1995-03-16 The Procter & Gamble Company Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agent and at least one of a decongestant, an expectorant, an antihistamine and an antitussive
WO1999066919A1 (en) * 1998-06-19 1999-12-29 Mcneil-Ppc, Inc. Pharmaceutical composition containing a salt of acetaminophen and at least one other active ingredient

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985004589A1 (en) * 1984-04-09 1985-10-24 Abraham Sunshine Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
WO1988008302A1 (en) * 1987-04-24 1988-11-03 Abraham Sunshine Cough/cold mixtures comprising non-sedating antihistamine drugs
WO1988009656A1 (en) * 1987-06-08 1988-12-15 Abraham Sunshine Cough/cold mixtures comprising non-sedating antihistamine drugs
WO1995007103A1 (en) * 1993-09-07 1995-03-16 The Procter & Gamble Company Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agent and at least one of a decongestant, an expectorant, an antihistamine and an antitussive
WO1999066919A1 (en) * 1998-06-19 1999-12-29 Mcneil-Ppc, Inc. Pharmaceutical composition containing a salt of acetaminophen and at least one other active ingredient

Also Published As

Publication number Publication date
ZA200102605B (en) 2001-10-03
CO5200779A1 (en) 2002-09-27
PA8500101A1 (en) 2002-09-17
TWI243671B (en) 2005-11-21
AU4786701A (en) 2001-10-15
CN1422162A (en) 2003-06-04
AR025308A1 (en) 2002-11-20
PE20010576A1 (en) 2001-05-08
AU2001247867B2 (en) 2005-09-01
CR6232A (en) 2008-12-01
NZ520826A (en) 2004-07-30
WO2001074341A2 (en) 2001-10-11
BR0003648A (en) 2002-01-02
SG96611A1 (en) 2003-06-16

Similar Documents

Publication Publication Date Title
WO2001087306A8 (en) Compositions and methods for the treatment of colorectal cancer
AU2002213357A1 (en) Variant igg3 rituxan r and therapeutic use thereof
WO2002085857A3 (en) Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
WO2004006858A3 (en) Compounds, compositions, and methods employing same
MXPA01012184A (en) Dietary or pharmaceutical composition for use for the prevention or treatment of hyperoxaluria.
IL130424A (en) Compositions comprising ziprasidone or its hydrochloride monohydrate, their preparation and use thereof in the preparation of medicaments for treating psychosis
WO2002056912A3 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
EP1600168A3 (en) A pyrrolidineacetamide derivative alone or in combination for treatment of CNS disorder
CA2363990A1 (en) Use of glycyrrhizin in the treatment of mastitis
MXPA03008045A (en) Novel medicament compositions on the basis of anticholinergics and pde iv inhibitors.
AU2002243023A1 (en) Compositions for preventing and/or treating oral diseases
AU2002236647A1 (en) Method and device for administering medication and/or placebo
AU2002248319A1 (en) Pharmaceutical composition for the prevention and treatment of scar tissue
AU2001250821A1 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
WO2001062235A3 (en) A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
MXPA03003741A (en) Methods and compositions for the treatment of diseases of the eye.
EP2138175A3 (en) Formulations comprising valsartan for treating diabetes or microalbuminuria
WO2003015797A8 (en) Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and glucosamine
EE05211B1 (en) Use of saredutant and its pharmaceutically acceptable salts in the preparation of medicaments useful for the treatment or prevention of mood disorders, adaptive disorders, or mixed depressive disorders.
AU2002359618A1 (en) Medicinal compositions and therapeutic methods
NZ535611A (en) Pharmaceutical composition of a PDE4 or a PDE3/4 inhibitor and a histamine receptor antagonist
WO2002080895A3 (en) Treatment of malaria with farsenyl protein transferase inhibitors
AU2002325169A1 (en) Pharmaceutical composition for the prophylaxis and/or treatment of virus diseases
WO2001074341A3 (en) Composition for treating allergic and inflammatory conditions with cough containing a non-sedating histamine and an expectorant
AU2001295979A1 (en) Medicinal compositions, dose and method for treating malaria

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CZ DE DK DM DZ EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX MZ NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT TZ UA UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CZ DE DK DM DZ EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX MZ NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT TZ UA UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 520826

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 018076793

Country of ref document: CN

Ref document number: 2001247867

Country of ref document: AU

122 Ep: pct application non-entry in european phase
WWP Wipo information: published in national office

Ref document number: 520826

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 520826

Country of ref document: NZ

NENP Non-entry into the national phase

Ref country code: JP

WWG Wipo information: grant in national office

Ref document number: 2001247867

Country of ref document: AU